Teratogenic study of doxycycline

doi:10.1016/S0029-7844(97)00005-7

Obstetrics & Gynecology

Volume 89, Issue 4, April 1997, Pages 524-528

https://doi.org/10.1016/S0029-7844(97)00005-7 Get rights and content

Objective

To study the human teratogenic risk of doxycycline treatment during pregnancy.

Methods

Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities 1980–1992.

Results

Of 32,804 pregnant women who had infants with no defects in the study period (control group), 63 (0.19%) were treated with doxycycline. Of 18,515 pregnant women who had offspring with congenital abnormalities, 56 (0.30%) were treated with doxycycline, a rate that is higher than that of the control group (P = .01). However, the case-control pair analysis did not show a significantly higher rate of doxycycline treatment in the second and third months of gestation in any group of congenital abnormalities.

Conclusions

Treatment with doxycycline during pregnancy presents very little if any teratogenic risk to the fetus. Thus, if doxycycline treatment is necessary during pregnancy, there would appear to be no contraindication.

References (7)

ShepardTH
Catalog of teratogenic agents
(1992)
CzeizelAE
Analysis of medical indications for induced abortions [Hungarian with English abstract]
Orv Hetil
(1983)
CzeizelAE et al.
Evaluation of drug intake during pregnancy in the Hungarian Case-Control Surveillance of Congenital Anomalies
Teratology
(1990)

There are more references available in the full text version of this article.

Cited by (76)

Hidradenitis Suppurativa in Women
2022, A Comprehensive Guide to Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) disproportionately affects women of childbearing age and often leads to impairments in patients’ health-related quality of life. Women with HS face unique challenges related to menstruation, pregnancy, and lactation that require additional management considerations. This chapter reviews the hormonal theory of HS pathogenesis and how hormonal changes during the female life course may influence disease progression and severity. Management of the pregnant HS patient is reviewed. Further investigation is needed to characterize the efficacy and safety of HS treatments in pregnant and lactating women.
Drugs in renal disease and pregnancy
2019, Best Practice and Research: Clinical Obstetrics and Gynaecology
This review aims to summarise historic and the latest evidence of commonly used drugs in pregnant women with chronic kidney disease (CKD). Data regarding safety of drugs in breastfeeding are also described. Practical recommendations are made on the use of newer agents that have limited information of use in pregnant women with CKD. Pharmacokinetic and dynamic issues are outlined, and general principles for prescribing drugs in pregnant women with CKD are listed. Resources to investigate drug safety are presented.
Drugs and Environmental Agents in Pregnancy and Lactation: Teratology, Epidemiology
2016, Obstetrics: Normal and Problem Pregnancies
Anti-infective Agents
2015, Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Third Edition
Infections may be hazardous to the health of the mother, the course of pregnancy, and the unborn child. They can lead to premature labor or premature rupture of membranes and thereby increase the risk for spontaneous abortion and prematurity. Furthermore, certain germs can pass to the unborn child and harm it directly. Therefore, an anti-infective treatment which should be both effective and safe for the mother and the unborn child is often required. The use of penicillines and older cephalosporines is well documented and considered to be safe. Consequently, they are the drug of choice during pregnancy. In selected cases of bacterial resistance or intolerance to first-line antibiotics, other anti-infective agents might be recommended. Especially for life-threatening infections, a therapy with not so well-tried agents might be needed. The potential benefit of treatment in such cases most often outbalances the potential risk for the unborn child.
Tetracyclines, Glycylcyclines, and Chloramphenicol
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
Malaria prevention in the pregnant traveller: A review
2014, Travel Medicine and Infectious Disease
Citation Excerpt :
In a third study, eight pregnant women from Thailand and 18 pregnant women from Zambia received a three day course of AP during their third trimester of pregnancy. No miscarriages or birth defects were detectable [38]. Doxycycline is considered as contraindicated in pregnant women and children below the age of 8 years.
Malaria is still a major threat to health in tropical regions. Particular attention should be directed to malaria prevention in infants and pregnant women as they are at high risk for plasmodial infection and complicated malaria. In this review, we summarize and discuss current evidence on malaria prevention in pregnant travellers.
As neither anti-mosquito measures nor anti-malarial drugs have been proven to be unequivocally safe or toxic in pregnant women, the individual risk assessment should take into account the risk of transmission at the destination, the benefit of travelling despite being pregnant as well as the individual risk perception. All three factors may differ in various groups of travellers like tourist travellers, expatriate travellers as well as those visiting friends and relatives.
For pregnant women, mefloquine appears to be the drug of choice for prophylaxis and stand by-therapy if no contraindications exist – despite recent renewed warnings related to prolonged side effects. In areas with high resistance against mefloquine or in women with contraindications to mefloquine, atovaquone–proguanil or artemether–lumefantrine should be considered as an option for stand-by emergency therapy. Nevertheless, evidence on the safety of anti-malarials especially during the first trimester is still insufficient.

View all citing articles on Scopus

View full text

Teratogenic study of doxycycline

Objective

Methods

Results

Conclusions

Catalog of teratogenic agents

Analysis of medical indications for induced abortions [Hungarian with English abstract]

Orv Hetil

Evaluation of drug intake during pregnancy in the Hungarian Case-Control Surveillance of Congenital Anomalies

Teratology